Systemic Sclerosis (SSc) Clinical Trials

49 recruitingLast updated: June 18, 2026

There are 49 actively recruiting systemic sclerosis (ssc) clinical trials across 34 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3, Phase 4. Top locations include Hangzhou, Zhejiang, China, London, United Kingdom, Ann Arbor, Michigan, United States. Updated daily from ClinicalTrials.gov.


Systemic Sclerosis (SSc) Trials at a Glance

49 actively recruiting trials for systemic sclerosis (ssc) are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 1 with 18 trials, with the heaviest enrollment activity in Hangzhou, London, and Ann Arbor. Lead sponsors running systemic sclerosis (ssc) studies include Hacettepe University, The Children's Hospital of Zhejiang University School of Medicine, and Beijing GoBroad Hospital.

Browse systemic sclerosis (ssc) trials by phase

Treatments under study

About Systemic Sclerosis (SSc) Clinical Trials

Looking for clinical trials for Systemic Sclerosis (SSc)? There are currently 49 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic Sclerosis (SSc) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic Sclerosis (SSc) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 49 trials

Recruiting
Phase 1

US Zamto-cel Autoimmune Diseases

Systemic Lupus ErythematosusDiffuse Cutaneous Systemic SclerosisSystemic Sclerosis (SSc)+1 more
Miltenyi Biomedicine GmbH48 enrolled1 locationNCT06708845
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis

Healthy VolunteersSclerodermaSystemic Sclerosis (SSc)+1 more
Prolium Bioscience, Inc74 enrolled2 locationsNCT07641634
Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

SclerodermaRheumatoid Arthritis (RA)Sjogren Syndrome+6 more
Artiva Biotherapeutics, Inc.90 enrolled52 locationsNCT06991114
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled21 locationsNCT06308978
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting
Phase 1Phase 2

Controlling Hyperactive Immunity With Long-lived Lymphocytes

Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Phase 2

Intralesional Injection of STS in Treatment of Calcinosis

DermatomyositisSystemic Sclerosis (SSc)Mixed Connective Tissue Disease (MCTD)+1 more
Robyn T. Domsic, MD, MPH20 enrolled1 locationNCT06672822
Recruiting
Phase 1

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Neuromyelitis Optica Spectrum Disorder (NMOSD)+6 more
Polina Stepensky120 enrolled1 locationNCT07085676
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

Systemic Sclerosis (SSc)
argenx81 enrolled74 locationsNCT06655155
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Early Phase 1

MTS109 in Patients With Refractory Autoimmune Diseases

Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis (SSc)+2 more
Shanghai Changzheng Hospital15 enrolled1 locationNCT07526350
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Not Applicable

Systemic Sclerosis DIet for GastrointESTinal Symptoms

Systemic Sclerosis (SSc)
University of Michigan60 enrolled1 locationNCT07402226
Recruiting

Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Sclerosis (SSc)+2 more
Cairo University460 enrolled1 locationNCT07277491
Recruiting
Phase 1

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)
Beijing GoBroad Hospital27 enrolled1 locationNCT06822881
Recruiting
Phase 1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07104721
Recruiting

Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images

Systemic Sclerosis (SSc)Calcinosis Cutis
Yale University56 enrolled1 locationNCT07228429
Recruiting
Phase 2

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

SclerodermaSystemic Sclerosis (SSc)
Zura Bio Inc80 enrolled51 locationsNCT06843239
Recruiting
Phase 1

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathySystemic Sclerosis (SSc)+2 more
Therorna12 enrolled1 locationNCT07413341
Recruiting

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Multiple SclerosisRheumatoid Arthritis (RA)Dermatomyositis+4 more
Kyverna Therapeutics70 enrolled1 locationNCT07403188